Several oncogenic mechanisms have been associated with PD-L1 expression, such as tumor-suppressive PTEN gene mutation or deletion, pro-oncogenic PI3K path activation, AKT/mTOR, NF-kB, and MAPK (mitogen-activated protein kinase, MEK/ERK) pathways deregulation. The gene discussed is CD274; the disease is neoplasm.